Ray Suman Kumar, Mukherjee Sukhes
Independent Researcher, India.
Department of Biochemistry, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh-462020, India.
Infect Disord Drug Targets. 2023;23(2):e310822208284. doi: 10.2174/1871526522666220831101802.
A new COVID-19 variant that no one currently wants has emerged with the start of the new year. Omicron, which was first discovered in November of last year, was only just beginning to be understood when another strain uncovered in France made headlines. On January 4, 2022, news of the variant exploded on social media, but cases of what is now known as variant B.1.640.2 (IHU) were initially discovered about two months prior. Evidence is still being gathered, but internet misinformation regarding the latest coronavirus variety is already rampant, as it was with Omicron. The majority of existing vaccines target SARS-spike CoV-2's protein, which the virus utilizes to enter and infect cells. Epidemiologists and virologists worldwide are concerned about the virus' spike protein, which plays a key role in how your body identifies and reacts to the virus. Spike proteins are produced, recognized, and defended against by our immune system. Your body and the vaccines you have had injected into your system have a far harder time fighting the virus when the amino acids in a protein are altered or removed.
随着新年的开始，一种目前无人想要的新型新冠病毒变种出现了。奥密克戎于去年11月首次被发现，当在法国发现的另一种毒株成为头条新闻时，人们才刚刚开始了解它。2022年1月4日，该变种的消息在社交媒体上迅速传播，但现在被称为B.1.640.2（IHU）变种的病例最初是在大约两个月前被发现的。证据仍在收集之中，但与最新冠状病毒变种有关的网络错误信息已经泛滥，奥密克戎出现时也是如此。现有的大多数疫苗针对的是新冠病毒刺突蛋白，病毒利用这种蛋白进入并感染细胞。全球的流行病学家和病毒学家都对该病毒的刺突蛋白感到担忧，它在人体识别和应对病毒的方式中起着关键作用。刺突蛋白由我们的免疫系统产生、识别并抵御。当蛋白质中的氨基酸发生改变或缺失时，人体以及注入体内的疫苗对抗病毒的难度就会大大增加。
